Compare Abbott Laboratories (ABT) vs Intuit Inc. (INTU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Intuit Inc. — how do they compare? Abbott Laboratories trades at $95.48 (market cap $166.94B), while Intuit Inc. trades at $273.5 (market cap $76.91B). The key difference: Abbott Laboratories is far larger — about 2.2× Intuit Inc.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | INTU | |
|---|---|---|
Market Cap | $166.94B | $76.91B |
Sector | Health | Technology |
52-Week High | $136.62 | $807.39 |
52-Week Low | $82.57 | $255.07 |
Enterprise Value | $193.69B | $75.37B |
Dividend Yield | 2.63% | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Intuit (INTU) trades at $272.14, down 1.17% on the day, amid a bearish technical signal and ongoing securities fraud investigations. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $12.80 versus $12.57 expected, and robust profitability with a net income margin of 21.91%. Revenue growth is steady, climbing from $12.7B in 2022 to $18.8B in 2025, supported by a high gross profit margin of 79.96%.
Despite solid fundamentals, INTU faces significant headwinds from legal scrutiny and negative sentiment, with a 20% stock drop triggering multiple fraud probes. Analyst consensus remains bullish with a $433.69 price target, but near-term risks from litigation and competitive pressures in tax software could limit upside. The stock's current valuation at a P/E of 16.6 offers a margin of safety if growth persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
